脑梗死患者颈动脉斑块的临床观察与治疗初探
|
摘要
目的探讨阿托伐他汀钙片对脑梗死患者颈动脉粥样硬化斑块的临床治疗效果。方法选择2017年1月～2018年1月来我院进行治疗的50例脑梗死患者作为此次研究对象,将其分为对照组与观察组,每组25例。对照组采用常规肠溶阿司匹林治疗,观察组给予阿托伐他汀钙片进行治疗,比较两组患者双侧颈动脉斑块积分。结果入院时以及治疗1月后,观察组患者颈动脉斑与对照组比较,差异无统计学意义(P> 0.05)。对照组在治疗3、6月后颈动脉斑块增加,差异有统计学意义(P <0.05)。观察组在治疗3、6月后颈动脉斑块减小,差异有统计学意义(P <0.05)。入院时,观察组患者血脂水平对照组比较,差异无统计学意义(P> 0.05);治疗1、3、6月后,两组患者TC、 TG、 HDL-C、 LDL-C水平均优于入院时,差异有统计学意义(P <0.05)。但观察组患者TC、 TG、 HDL-C、 LDL-C水平显著优于对照组患者,差异有统计学意义(P <0.05)。结论使用阿托伐他汀钙片治疗脑梗死患者颈动脉粥样硬化斑块的临床治疗效果显著,不仅可以稳定甚至减轻动脉粥样硬化,还可以降低患者血脂,值得临床推广应用。
Objective To explore the clinical curative effect of atorvastatin calcium tablets on carotid atherosclerotic plaque in patients with cerebral infarction. Methods 50 patients with cerebral infarction who were treated in our hospital from January 2017 to January 2018 were selected as research objects. They were divided into the control group and the observation group, with 25 cases in each group. The control group was treated with conventional enteric coated aspirin while the observation group was treated with atorvastatin calcium tablets. Scores of bilateral carotid plaques were compared between the two groups. Results There was no significant difference in carotid plaques between the observation group and the control group at admission and 1 month after treatment(P >0.05). In control group, carotid plaques increased after treatment for 3 and 6 months. The difference was statistically significant(P < 0.05). Carotid plaque decreased in the observation group after treatment for 3 and 6 months. The difference was statistically significant(P < 0.05). On admission, there was no significant difference in blood lipid levels between the observation group and the control group(P > 0.05). After 1, 3, 6 months of treatment, the levels of TC, TG, HDL-C and LDL-C in the two groups were better than those at admission, and the difference was statistically significant(P < 0.05). But the levels of TC, TG, HDL-C and LDL-C in the observation group were significantly higher than those in the control group, and the difference was statistically significant(P < 0.05).Conclusion Atorvastatin calcium tablets in the treatment of carotid atherosclerotic plaque in patients with cerebral infarction have a significant clinical curative effect. It can not only stabilize or even alleviate atherosclerosis, but also reduce blood lipid, which is worthy of clinical promotion and application.
Objective To explore the clinical curative effect of atorvastatin calcium tablets on carotid atherosclerotic plaque in patients with cerebral infarction. Methods 50 patients with cerebral infarction who were treated in our hospital from January 2017 to January 2018 were selected as research objects. They were divided into the control group and the observation group, with 25 cases in each group. The control group was treated with conventional enteric coated aspirin while the observation group was treated with atorvastatin calcium tablets. Scores of bilateral carotid plaques were compared between the two groups. Results There was no significant difference in carotid plaques between the observation group and the control group at admission and 1 month after treatment(P >0.05). In control group, carotid plaques increased after treatment for 3 and 6 months. The difference was statistically significant(P < 0.05). Carotid plaque decreased in the observation group after treatment for 3 and 6 months. The difference was statistically significant(P < 0.05). On admission, there was no significant difference in blood lipid levels between the observation group and the control group(P > 0.05). After 1, 3, 6 months of treatment, the levels of TC, TG, HDL-C and LDL-C in the two groups were better than those at admission, and the difference was statistically significant(P < 0.05). But the levels of TC, TG, HDL-C and LDL-C in the observation group were significantly higher than those in the control group, and the difference was statistically significant(P < 0.05).Conclusion Atorvastatin calcium tablets in the treatment of carotid atherosclerotic plaque in patients with cerebral infarction have a significant clinical curative effect. It can not only stabilize or even alleviate atherosclerosis, but also reduce blood lipid, which is worthy of clinical promotion and application.
引文
[1]钱梅芳,张素会,张会丛.阿司匹林联合辛伐他汀治疗脑梗死患者颈动脉斑块的临床研究[J].医学美学美容旬刊, 2015, 24(6):749-750.
[2]陈卓友,包仕尧.舒降之治疗脑梗死患者颈动脉粥样硬化斑块的临床研究[J].临床神经病学杂志, 2004, 17(1):23-25.
[3]刘平.阿托伐他汀钙联合氯吡格雷治疗脑梗死患者颈动脉粥样硬化的临床观察[J].中外医学研究, 2015(10):52-53.
[4]于建刚,钱建东,徐红,等.阿托伐他汀钙对脑梗死患者颈动脉斑块影响的临床研究[J].华西医学, 2008(6):14-15.
[5]黄太权,范华昌.雷氏丹参片治疗脑梗塞患者颈动脉粥样硬化斑块的临床研究[J].中成药, 2006, 28(6):832-834.
[6]张新颜,张建平,方岩.阿托伐他汀治疗脑梗死患者颈动脉粥样硬化斑块的临床研究[J].中国实用神经疾病杂志, 2007, 10(2):13-14.
[7]陈卓友,包仕尧.舒降之治疗脑梗死患者颈动脉粥样斑块临床研究[C]//中华医学会第七次全国神经病学学术会议论文汇编. 2004:7-9.
[8]王塑华,孙佳凡.阿托伐他汀治疗脑梗死合并颈动脉粥样硬化斑块的临床研究[J].中国药房, 2009(35):2762-2764.
[9]吴卫,卢理英,邹颖.阿托伐他汀治疗脑梗死患者颈动脉粥样硬化斑块的临床观察[J].海峡药学, 2012, 24(5):204-205.
[10]汤莉莹,张琴,赵霞,等.前列腺素E1脂微球制剂治疗急性脑梗死患者颈动脉粥样硬化的临床观察[J].中国医师杂志, 2009, 11(7):978-980.
[11]刘子凡,许治强,梁伟翔,等.脑梗死患者颈动脉内膜中层厚度改变及危险因素初探[J].新医学, 2004, 35(9):547-548.
[12]姜瑾,薛冰.老年高血压患者颈动脉粥样硬化病变与脑梗死关系初探[J].中华现代临床医学杂志, 2006:152-153.
[13]陆智东,潘庆登,黄永康.冠心病患者血脂异常及炎症反应与颈动脉斑块形成关系的初探[J].中国临床新医学, 2014, 7(3):209-211.
[14]王涛.颈动脉狭窄的手术治疗及颈动脉斑块细菌感染病原学研究初探[D].北京:首都医科大学, 2011:89-90.
[15]岳蕴华,白旭东,张小宁,等.普罗布考联合阿托伐他汀对脑梗死患者血清hs-CRP、ox-LDL、MMP-9水平及颈动脉斑块的影响[J].中国神经精神疾病杂志,2014(11):641-645.
[16]陈刚.血糖与高血压患者颈动脉粥样斑块的关系初探[J].中国临床医药研究杂志, 2008:1-3.
[2]陈卓友,包仕尧.舒降之治疗脑梗死患者颈动脉粥样硬化斑块的临床研究[J].临床神经病学杂志, 2004, 17(1):23-25.
[3]刘平.阿托伐他汀钙联合氯吡格雷治疗脑梗死患者颈动脉粥样硬化的临床观察[J].中外医学研究, 2015(10):52-53.
[4]于建刚,钱建东,徐红,等.阿托伐他汀钙对脑梗死患者颈动脉斑块影响的临床研究[J].华西医学, 2008(6):14-15.
[5]黄太权,范华昌.雷氏丹参片治疗脑梗塞患者颈动脉粥样硬化斑块的临床研究[J].中成药, 2006, 28(6):832-834.
[6]张新颜,张建平,方岩.阿托伐他汀治疗脑梗死患者颈动脉粥样硬化斑块的临床研究[J].中国实用神经疾病杂志, 2007, 10(2):13-14.
[7]陈卓友,包仕尧.舒降之治疗脑梗死患者颈动脉粥样斑块临床研究[C]//中华医学会第七次全国神经病学学术会议论文汇编. 2004:7-9.
[8]王塑华,孙佳凡.阿托伐他汀治疗脑梗死合并颈动脉粥样硬化斑块的临床研究[J].中国药房, 2009(35):2762-2764.
[9]吴卫,卢理英,邹颖.阿托伐他汀治疗脑梗死患者颈动脉粥样硬化斑块的临床观察[J].海峡药学, 2012, 24(5):204-205.
[10]汤莉莹,张琴,赵霞,等.前列腺素E1脂微球制剂治疗急性脑梗死患者颈动脉粥样硬化的临床观察[J].中国医师杂志, 2009, 11(7):978-980.
[11]刘子凡,许治强,梁伟翔,等.脑梗死患者颈动脉内膜中层厚度改变及危险因素初探[J].新医学, 2004, 35(9):547-548.
[12]姜瑾,薛冰.老年高血压患者颈动脉粥样硬化病变与脑梗死关系初探[J].中华现代临床医学杂志, 2006:152-153.
[13]陆智东,潘庆登,黄永康.冠心病患者血脂异常及炎症反应与颈动脉斑块形成关系的初探[J].中国临床新医学, 2014, 7(3):209-211.
[14]王涛.颈动脉狭窄的手术治疗及颈动脉斑块细菌感染病原学研究初探[D].北京:首都医科大学, 2011:89-90.
[15]岳蕴华,白旭东,张小宁,等.普罗布考联合阿托伐他汀对脑梗死患者血清hs-CRP、ox-LDL、MMP-9水平及颈动脉斑块的影响[J].中国神经精神疾病杂志,2014(11):641-645.
[16]陈刚.血糖与高血压患者颈动脉粥样斑块的关系初探[J].中国临床医药研究杂志, 2008:1-3.